Epetraborole  (Synonyms: GSK-2251052; AN 3365)

Epetraborole (GSK2251052) is a leucyl-tRNA synthetase (LeuRS) inhibitor (IC₅₀=0.31 μM), thereby inhibiting protein synthesis. Epetraborole can be used in multidrug-resistant gram-negative pathogens infection research^[1][2][3].

IC50: 0.31 μM (LeuRS)^[3]

Epetraborole (0-32 μg/mL) shows anti-bacterial activity against key gram-negative aerobic and anaerobic pathogens and gram-positive anaerobes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

237.06

C₁₁H₁₆BNO₄

1093643-37-8

OCCCOC1=C2C([C@H](OB2O)CN)=CC=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Goldstein EJ, et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57(5):2401-4.  [Content Brief]

  [2]. O'Dwyer K, et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98.  [Content Brief]

  [3]. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52.  [Content Brief]